Delving into the Latest Updates on Axceso Biopharma Co. Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Neoplasms

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Neoplasms	2
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6

Top 5 Target	Count

SIRT1(NAD-dependent deacetylase sirtuin 1)	3
AXL(AXL receptor tyrosine kinase)	1
Syk(Spleen tyrosine kinase)	1
PDL1(Programmed death-ligand 1)	1

Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with a poor prognosis and decreased patient survival. It is intimately linked to AXL overexpression and AXL hyperactivation. Here, we explored the therapeutic potential of AX-0085, a small molecule AXL inhibitor. While AX-0085 was previously characterized in the context of lung adenocarcinoma, this study demonstrates its application in triple-negative breast cancer (TNBC) models. AX-0085 exhibited high binding affinity to the ATP binding site located beneath the conserved glycine-rich loop (P-loop) that links the β1 and β2 strands of the AXL kinase domain. Furthermore, it was demonstrated that the benzamide group of AX-0085 and LyS567's Nζ atom could generate a hydrogen bond. AX-0085 efficiently suppressed the AXL/GAS6 signaling pathway activation in TNBC cells in vitro, which in turn prevented AXL/GAS6 signaling-dependent pro-cancerous behavior like cell proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT). In TNBC, an AX-0085-induced cell cycle arrest that took place during the G1 phase reduced the expression of CYCLIN E and CDK2. Additionally, AX-0085 facilitated apoptotic cell death in TNBC. Treatment of AX-0085 on in vivo mouse xenografts transplanted with 4 T1 cells showed a significant tumor reduction. Thus, our findings demonstrate that AX-0085 has an effective therapeutic role in TNBC by inhibiting AXL activation.

10 Sep 2024·International Journal of Stem Cells

An Efficient Endothelial Cell Differentiation Protocol Using Bioactive Lipid O-Cyclic Phytosphingosine-1-Phosphate in Human Embryonic Stem Cells

Article

Author: Antao, Ainsley Mike ; Park, Young Jun ; Ramakrishna, Suresh ; Kim, Kye-Seong ; Jo, Ki-Sang ; Jo, Won-Jun ; Choi, Myeong-Jun ; Karapurkar, Janardhan Keshav

Bioactive lipids like sphingosine-1-phosphate (S1P) and lysophosphatidic acid have gained significant attention as signaling molecules with regulatory roles in stem cell proliferation and differentiation. The novel chemically synthesized sphingosine metabolite O-cyclic phytosphingosine-1-phosphate (cP1P) is derived from phytosphingosine-1-phosphate (P1P) and shares structural similarities with S1P. Previously, the role of cP1P in regulating ALK3/BMPR signaling during cardiomyocyte differentiation from human embryonic stem cells (hESCs) was demonstrated. In this study, the applicability of cP1P for endothelial cells (ECs) differentiation from hESCs was investigated an efficient method to obtain a high yield of functional ECs over several passages was standardized. The ECs derived from hESCs showed cellular and molecular characteristics similar to the native ECs. Thus, the results of this study open avenues for further research into cP1P-based stem cell differentiation for regenerative therapies.

30 Nov 2023·International Journal of Stem Cells

Corrigendum to "Cyclic Phytosphingosine-1-Phosphate Primed Mesenchymal Stem Cells Ameliorate LPS-Induced Acute Lung Injury in Mice"

Author: Park, Youngheon ; Kim, Kye-Seong ; Lee, Se Bi ; Park, Young Jun ; Baek, Hyosin ; Kwon, Jae-Woo ; Cha, Sang-Ryul ; Na, Sunghun ; Yang, Se-Ran ; Lee, Jooyeon ; Choi, Myeong Jun ; Hong, Seok-Ho ; Jang, Jimin ; Park, Jaehyun

100 Deals associated with Axceso Biopharma Co. Ltd.

Login to view more data

100 Translational Medicine associated with Axceso Biopharma Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

4

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AX-0085 ( AXL )	Triple Negative Breast Cancer More	Preclinical
AXN-1901 ( SIRT1 )	Parkinson Disease More	Preclinical
AXB-1701 ( SIRT1 )	Sepsis More	Preclinical
AXN-1501 ( SIRT1 )	Alzheimer Disease More	Preclinical
EP4215533 ( PDL1 )	Neoplasms More	Discovery